Drug Design of Antiobesity Carbonic Anhydrase Inhibitors (379 views)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; 66(DECEMBERSPEC.I): 241-254.
Export to BibTeX Export to EndNote
Paper type: Book Chapter,
Impact factor: 1.156, 5-year impact factor: 1.164
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84889494522&partnerID=40&md5=a2d479fa8baf89c8bf6b6e9e52387279
Keywords: Carbonic Anhydrases-New Targets In Obesity Treatment, Drug Design Of Antiobesity Carbonic Anhydrase Inhibitors, Zonisamide (zns)-Antiepileptic Drugs As Adjunctive Therapy For Refractory Partial Seizures, Diagnosis, Amfepramone, Biomag, Desobesi M, Dualid S, Fenproporex, Fluoxetine, Hipofagin S, Inibex S, Lipiblock, Mazindol, Moderine, Placebo, Plenty, Redulip, Rimonabant, Saciette, Sertraline, Sibus, Sibutramine, Sigran, Slenfig, Tetrahydrolipstatin, Unclassified Drug, Vazy, Article, Bariatric Surgery, Blood Clotting Disorder, Body Mass, Bulimia, Clinical Trial, Cognitive Therapy, Computer Assisted Tomography, Constipation, Defecation, Degenerative Disease, Depression, Diabetes Mellitus, Diastolic Blood Pressure, Disease Association, Dual Energy X Ray Absorptiometry, Echography, Fatty Liver, Flatulence, Gastrointestinal Symptom, Headache, Heart Palpitation, Heart Rate, Human, Impedance, Insomnia, Kinesiotherapy, Mortality, Nuclear Magnetic Resonance Imaging, Prevalence, Side Effect, Sleep Apnea Syndrome, Systolic Blood Pressure, Unspecified Side Effect, Xerostomia,
Affiliations:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, Via Mezzocannone 16, 80134 Naples, Italy
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Polo Scientifico, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
rea de Endocrinologie, Faculdade de Medicina Da Universidade de S o Paulo (FMUSP), Brazil
Grupo de Obesidade e S ndrome Metab lica, Hospital Das Cl nicas (HC-FMUSP), Liga de Obesidade Infantil da FMUSP, Brazil
Laborat rio de Carboidratos e Radioimunoensaio (LIM 18) da FMUSP, Brazil
References:
Not available.
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; 66(DECEMBERSPEC.I): 241-254.
Export to BibTeX Export to EndNote
Paper type: Book Chapter,
Impact factor: 1.156, 5-year impact factor: 1.164
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84889494522&partnerID=40&md5=a2d479fa8baf89c8bf6b6e9e52387279
Keywords: Carbonic Anhydrases-New Targets In Obesity Treatment, Drug Design Of Antiobesity Carbonic Anhydrase Inhibitors, Zonisamide (zns)-Antiepileptic Drugs As Adjunctive Therapy For Refractory Partial Seizures, Diagnosis, Amfepramone, Biomag, Desobesi M, Dualid S, Fenproporex, Fluoxetine, Hipofagin S, Inibex S, Lipiblock, Mazindol, Moderine, Placebo, Plenty, Redulip, Rimonabant, Saciette, Sertraline, Sibus, Sibutramine, Sigran, Slenfig, Tetrahydrolipstatin, Unclassified Drug, Vazy, Article, Bariatric Surgery, Blood Clotting Disorder, Body Mass, Bulimia, Clinical Trial, Cognitive Therapy, Computer Assisted Tomography, Constipation, Defecation, Degenerative Disease, Depression, Diabetes Mellitus, Diastolic Blood Pressure, Disease Association, Dual Energy X Ray Absorptiometry, Echography, Fatty Liver, Flatulence, Gastrointestinal Symptom, Headache, Heart Palpitation, Heart Rate, Human, Impedance, Insomnia, Kinesiotherapy, Mortality, Nuclear Magnetic Resonance Imaging, Prevalence, Side Effect, Sleep Apnea Syndrome, Systolic Blood Pressure, Unspecified Side Effect, Xerostomia,
Affiliations:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, Via Mezzocannone 16, 80134 Naples, Italy
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Polo Scientifico, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
rea de Endocrinologie, Faculdade de Medicina Da Universidade de S o Paulo (FMUSP), Brazil
Grupo de Obesidade e S ndrome Metab lica, Hospital Das Cl nicas (HC-FMUSP), Liga de Obesidade Infantil da FMUSP, Brazil
Laborat rio de Carboidratos e Radioimunoensaio (LIM 18) da FMUSP, Brazil
References:
Not available.
Drug Design of Antiobesity Carbonic Anhydrase Inhibitors
The obesity is a disorder with increasing prevalence in the last decodes, which makes it a real global epidemy. The obesity is a bind of trigger factor or aggravating factor for others diseases such as diabetes mellitus, hyperlipidemia, cerebral and cardiovascular diseases, coagulation disorders, articular and degenerative diseases, hepatic esteatosis sleeping apnea and others. In patients with morbid obesity, the associated diseases have increased risk of complications with higher mortality. The medical attitude in relation to obesity have changed nowadays particularly in the recent years, improving its prevention as well as the treatment. Copyright Moreira Jr. Editora
The obesity is a disorder with increasing prevalence in the last decodes, which makes it a real global epidemy. The obesity is a bind of trigger factor or aggravating factor for others diseases such as diabetes mellitus, hyperlipidemia, cerebral and cardiovascular diseases, coagulation disorders, articular and degenerative diseases, hepatic esteatosis sleeping apnea and others. In patients with morbid obesity, the associated diseases have increased risk of complications with higher mortality. The medical attitude in relation to obesity have changed nowadays particularly in the recent years, improving its prevention as well as the treatment. Copyright Moreira Jr. Editora
Drug Design of Antiobesity Carbonic Anhydrase Inhibitors
No results. |
379 views. Last view on Friday 13 September 2024, 16:37:21
ibb.cnr.it
